Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B

PLoS Neglected Tropical Diseases

Volumn 10, Issue 1, 2016, Pages

  Morizot, Gloria ^a   Jouffroy, Romain ^b   Faye, Albert ^c   Chabert, Paul ^d   Belhouari, Katia ^e   Calin, Ruxandra ^e   Charlier, Caroline ^f   Miailhes, Patrick ^d   Siriez, Jean Yves ^c   Mouri, Oussama ^e   Yera, Hélène ^g   Gilquin, Jacques ^f   Tubiana, Roland ^e   Lanternier, Fanny ^f   Mamzer, Marie France ^b   Legendre, Christophe ^b   Peyramond, Dominique ^d   Caumes, Eric ^e   Lortholary, Olivier ^f   Buffet, Pierre ^e,h  

^a INSTITUT PASTEUR   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g Institut Cochin   (France)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE; MILTEFOSINE; AMPHOTERICIN B; ANTIMONY; ANTIPROTOZOAL AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHEMOTHERAPY; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; NEPHRECTOMY; PARASITEMIA; POLYMERASE CHAIN REACTION; RELAPSE; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; WEIGHT REDUCTION; DRUG EFFECTS; INFANT; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; TREATMENT OUTCOME;

ADULT; AGED; AMPHOTERICIN B; ANTIMONY; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; INFANT; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84969423579     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004304     Document Type: Article

References (18)

1. Petrela R, Kuneshka L, Foto E, Zavalani F, Gradoni L, (2010) Pediatric visceral leishmaniasis in Albania: a retrospective nalysis of 1,210 consecutive hospitalized patients (1995–2009). PLoS Negl Trop Dis. pp. e814. doi:810.1371/journal.pntd.0000814. doi: 10.1371/journal.pntd.0000814 20838650
2. Buffet PA, Rosenthal E, Gangneux JP, Lightburne E, Couppie P, et al. (2011) [Therapy of leishmaniasis in France: consensus on proposed guidelines]. Presse Med 40: 173–184. doi: 10.1016/j.lpm.2010.09.023 21106333
3. Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, et al. (2010) 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med 11: 670–673. doi: 10.1111/j.1468-1293.2010.00846.x 20500233
4. Cota GF, de Sousa MR, Rabello A, (2011) Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5: e1153. doi: 10.1371/journal.pntd.0001153 21666786
5. Jarvis JN, Lockwood DN, (2013) Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 26: 1–9. doi: 10.1097/QCO.0b013e32835c2198 23221770
6. de Valliere S, Mary C, Joneberg JE, Rotman S, Bullani R, et al. (2009) AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 81: 209–212. 19635871
7. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, et al. (2008) Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr 48: 13–19. doi: 10.1097/QAI.0b013e318166af5d 18300698
8. Sindermann H, Engel KR, Fischer C, Bommer W, (2004) Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39: 1520–1523. 15546090
9. (2010) Control of the leishmaniases. World Health Organ Tech Rep Ser: xii-xiii, 1–186, back cover.
10. Mary C, Faraut F, Drogoul MP, Xeridat B, Schleinitz N, et al. (2006) Reference values for Leishmania infantum parasitemia in different clinical presentations: quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up. Am J Trop Med Hyg 75: 858–863. 17123977
11. Lachaud L, Chabbert E, Dubessay P, Dereure J, Lamothe J, et al. (2002) Value of two PCR methods for the diagnosis of canine visceral leishmaniasis and the detection of asymptomatic carriers. Parasitology 125: 197–207. 12358417
12. Davidson RN, Russo R, (1994) Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 19: 560. 7811891
13. Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, et al. (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53: e91–98. doi: 10.1093/cid/cir521 21890763
14. Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, et al. (2011) Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152–158. doi: 10.1093/cid/cir674 22016502
15. Tuon FF, Bombonatto GM, Battaglin ER, Sakumoto MH, Amato VS, et al. (2014) Reactivation of mucosal and cutaneous leishmaniasis in a renal transplanted patient. Am J Trop Med Hyg 91: 81–83. doi: 10.4269/ajtmh.13-0578 24732458
16. Clemente W, Vidal E, Girao E, Ramos AS, Govedic F, et al. (2015) Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect 21: 89–95. doi: 10.1016/j.cmi.2014.09.002 25636932
17. Brustoloni YM, Cunha RV, Consolo LZ, Oliveira AL, Dorval ME, et al. (2010) Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil. Infection 38: 261–267. doi: 10.1007/s15010-010-0022-3 20508967
18. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, et al. (2009) Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 48: e16–22. doi: 10.1086/595710 19093811